Antimicrobial Resistance as an Economic Time Bomb: Why Drug- discovery incentives are a fiscal Policy Problem
Antimicrobial Resistance as an Economic Time Bomb: Why Drug- discovery incentives are a fiscal Policy Problem Abstract: This piece examines Antimicrobial Resistance (AMR) as a structural fiscal policy failure, rather than entirely a biological crisis, while situating the analysis within the geopolitical realignment of pharmaceutical supply chains and India’s evolving strategic position in global antibiotic economy. The argument draws on three intersecting datasets and methodologies. Epidemiological burden estimates are sourced from the Global Research on Antimicrobial Resistance (GRAM) consortium’s 2022 systematic analysis, which analysed 471 million individuals records in about 204 countries to conclude with mortality and disability adjusted life year (DALY) estimates for 23 pathogens and 88 pathogen-drug combinations (Murray et al., 2022). In Naghavi et al., 2024, longitudinal update extends this dataset through 2021 with forecasts to 2050, thus enabling analysis of trend rathe...